| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1372237 | Bioorganic & Medicinal Chemistry Letters | 2009 | 4 Pages |
Abstract
The calcitonin gene-related peptide (CGRP) receptor has been implicated in the pathogenesis of migraine. A class of urethanamide derivatives has been identified as potent inhibitors of the CGRP receptor. Compound 20 was found to be among the most potent (IC50 = 17 pM). It was shown to retain excellent aqueous solubility (>50 mg/mL, pH 7) while dramatically improving solution stability as compared to our previously disclosed development candidate, BMS-694153 (1).
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Andrew P. Degnan, Charles M. Conway, Richard A. Dalterio, Robert Macci, Stephen E. Mercer, Richard Schartman, Cen Xu, Gene M. Dubowchik, John E. Macor,